Health plans sue Big Pharma over co-pay coupons

Pharma's co-pay discounts have their fans--patients, certainly, and companies that have been able to boost prescriptions for high-priced drugs or hang onto sales as brands go off patent. But co-pay coupons and discount cards also have their detractors--namely, insurers and other payers trying to steer patients toward cheaper alternatives.

One way payers save money is by imposing larger co-pays on more expensive drugs, whether they are brand-name meds with generic competitors or pricier alternatives to other branded treatments. When drugmakers step in to cover part or all of an insurer's co-pay, it removes the incentive to use cheaper meds. And while patients may end up paying less, health plans still have to foot their share of the more expensive alternative.

Now, a consumer group and its affiliated union health plans are taking their coupon complaints to court. Community Catalyst and associated health funds sued 8 drugmakers using co-pay discounts to market their products. The health plans claim that co-pay assistance will increase their prescription drug costs substantially. "[T]hese kickbacks will increase health benefit providers' prescription drug costs by $32 billion over the next 10 years," one of the suits claims (as quoted by Bloomberg).

The 8 drugmakers--Pfizer ($PFE), Merck ($MRK), GlaxoSmithKline ($GSK), Amgen ($AMGN), Novartis ($NVS), AstraZeneca ($AZN), Bristol-Myers Squibb ($BMY) and Abbott Laboratories ($ABT)--have offered co-pay assistance on some of their biggest drugs, the lawsuits say. Among them: Pfizer's pain drug Celebrex and its cholesterol drug Lipitor, which now faces generic rivals; Merck's Nasonex allergy spray and cholesterol fighter Vytorin; and AstraZeneca's cholesterol pill Crestor and stomach drug Nexium.

- read the Bloomberg story
- get more from The Philadelphia Inquirer
- check out The Star Ledger report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.